Investor Type | Firm |
Type of Fund | Other |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) |
Stages | Expansion, MBO/LBO |
Investing | United Kingdom • France • Italy • Spain • Sweden • Switzerland • Europe • Norway • Ireland |
Investment Range | $5,000,000 - $300,000,000 |
Assets Under Management | $1,260,000,000 |
ArchiMed is an investment fund based in Terra Mundi, Lyon, France, with a specialized focus on the healthcare sector. They have assets under management of 1.26 billion dollars and invest primarily in BioTech, HealthTech, Medical Devices, and Hospital Services industries. Their investment range is between 5 million to 300 million dollars, with expertise in equity investments. ArchiMed's specialities include Expansion and MBO/LBO, which signifies their interest in growing mature companies and leveraging buyout opportunities. Their extensive portfolio covers a diverse spectrum within the healthcare industry, encapsulating biopharma, medtech, life sciences, healthcare IT, public safety, consumer health, care providers, and diagnostics. In biopharma, they target investments in entities dealing with small and large molecules, APIs, generic pharma, primary and specialty pharma, pharma delivery, and veterinary health. They also seek service providers offering bioanalytical, drug discovery, formulation services, CRO, CDMO, CLO, and specialized consulting. Medtech investments include companies involved in implants, equipment, consumables, services, and outsourcing in specialized fields such as Cardiovascular, Dental, Drug Delivery, Infection Control, Neurology, Ophthalmology, Orthopaedics, General Surgery, Wound Care, and Veterinary services. The life sciences sector includes investment in tools, equipment, consumables, and services related to bioprocessing and research. In the healthcare IT domain, they support both clinical and non-clinical solutions for care providers, care payer solutions, biopharma-related software, and outsourcing services. Their investments in public safety cover biocontrol, food safety, and environmental and healthcare-related testing, inspection, and certification (TIC), in addition to health at work initiatives. Furthermore, ArchiMed invests in the consumer health market which features cosmetics, health supplements, aesthetics, wellness, selfcare, and physiotherapy. Finally, care providers make up part of their focus, looking at homecare and specialized care delivery, along with outsourcing services, in addition to diagnostics that include in vitro and imaging solutions.
We invest in biopharma, medtech, life sciences, healthcare IT, public safety, consumer health, care providers, diagnostics. See below for details. Biopharma: Including small and large molecules, APIs, Generic, Primary and Specialty Pharma, Pharma delivery, Veterinary (animal health); Outsourcing Services such as bioanalytical, drug discovery or formulation services, CRO, CDMO, CLO or specialized consulting etc. Medtech: Including implants, equipment, consumables, services, outsourcing in field such as Cardiovascular, Dental, Drug Delivery, Infection control, Neuro, Ophtalmo, Orthopaedics, General surgery, Wound Care, Veterinary, etc. Life Sciences: Including tools, equipment, consumables and services, whether for Bioprocessing (upstream, downstream, final fill) and Research, etc. Healthcare IT: Clinical or Non-Clinical solutions for Care Providers, Care Payer solutions, Biopharma-related Software, Outsourcing services, etc. Public Safety: Biocontrol, Food safety, Environmental and Healthcare-related TIC (testing, inspection, certification), Health at work, etc. Consumer Health: Cosmetics, Health supplements, Aesthetics, Wellness, Selfcare, Physio, etc. Care Providers: Homecare, Specialized care delivery, Outsourcing services, etc. Diagnostics: Including In Vitro (IVD) and Imaging, etc.